World's Best Scientists 2026 revealed!
Award Badge
Immunology
Thailand
2026

D-Index & Metrics

Immunology

D-Index
63
Citations
16663
World Ranking
2993
National Ranking
2

Kiat Ruxrungtham publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kiat Ruxrungtham sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 469 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Kiat Ruxrungtham D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kiat Ruxrungtham sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 63 D-Index — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in Thailand Leader Award
  • 2025 - Research.com Immunology in Thailand Leader Award

Overview

Kiat Ruxrungtham is affiliated with Chulalongkorn University in Thailand. Their research is primarily focused on medicine with significant contributions in immunology and microbiology. The scientist's main subfields of study include infectious diseases, virology, epidemiology, immunology, and emergency medicine.

Their work emphasizes several core topics such as HIV research and treatment, HIV/AIDS research and interventions, SARS-CoV-2 and COVID-19 research, HIV-related health complications and treatments, HIV/AIDS drug development and treatment, viral gastroenteritis research and epidemiology, as well as vaccine coverage and hesitancy.

Frequent publication venues for Kiat Ruxrungtham include:

  • Asian Pacific Journal of Allergy and Immunology
  • Vaccines
  • Journal of the International AIDS Society
  • PLoS ONE
  • Clinical Infectious Diseases

Some of the recent papers authored by the scientist are:

  • COVID-19 and HIV infection co-pandemics and their impact: a review of the literature, 2021, AIDS Research and Therapy
  • Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates, 2021, Frontiers in Plant Science
  • Sleep Quality of Hospitalized Patients, Contributing Factors, and Prevalence of Associated Disorders, 2020, Sleep Disorders
  • HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective, 2023, Antiviral Therapy
  • DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice, 2021, PLoS ONE

Kiat Ruxrungtham collaborates frequently with several researchers, including:

  • Stephen J. Kerr
  • Anchalee Avihingsanon
  • Chutitorn Ketloy
  • Sivaporn Gatechompol
  • Eakachai Prompetchara

Best Publications

  • Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

    Netanya Sandler;Handan Wand;Annelys Roque;Matthew G Law

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Comprehensive serological profiling of human populations using a synthetic human virome

    George J. Xu;Tomasz Kula;Tomasz Kula;Qikai Xu;Qikai Xu;Mamie Z. Li;Mamie Z. Li

  • Life expectancy of HIV‐positive people after starting combination antiretroviral therapy: a meta‐analysis

    S Teeraananchai;SJ Kerr;SJ Kerr;J Amin;K Ruxrungtham

  • Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

    Calvin J Cohen;Jaime Andrade-Villanueva;Bonaventura Clotet;Jan Fourie

  • Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

    José Valdez Madruga;Daniel Berger;Marilyn McMurchie;Fredy Suter

  • HIV/AIDS in Asia

    Kiat Ruxrungtham;Tim Brown;Praphan Phanuphak

  • Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

    Anthony M. Mills;Mark Nelson;Dushyantha Jayaweera;Kiat Ruxrungtham

  • CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1 : results of the staccato randomised trial

    Jintanat Ananworanich;Angèle Gayet-Ageron;Michelle Le Braz;Wisit Prasithsirikul

  • Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

    John Gregson;Michele Tang;Nicaise Ndembi;Raph L Hamers

  • Cognitive Function and Neurodevelopmental Outcomes in HIV-Infected Children Older than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy: The PREDICT Neurodevelopmental Study

    Thanyawee Puthanakit;Jintanat Ananworanich;Saphonn Vonthanak;Pope Kosalaraksa

  • Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

    W. Phillip Law;Chris J. Duncombe;Apicha Mahanontharit;Mark A. Boyd

  • Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

    Jing Yuan;Sheng Guo;David Hall;Anna M Cammett

  • A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

    Gail V. Matthews;Anchalee Avihingsanon;Sharon R. Lewin;Sharon R. Lewin;Janaki Amin

  • Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

    W. Phillip Law;Gregory J. Dore;Chris J. Duncombe;Apicha Mahanontharit

  • A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse-Transcriptase Inhibitor-Based Regimens in HIV-Infected Patients Receiving Rifampicin: The N2R Study

    Weerawat Manosuthi;Weerawat Manosuthi;Somnuek Sungkanuparph;Preecha Tantanathip;Aroon Lueangniyomkul

  • Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

    Sharon Walmsley;Sharon Walmsley;Anchalee Avihingsanon;Jihad Slim;Douglas J Ward

  • Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.

    Anton L Pozniak;Javier Morales-Ramirez;Elly Katabira;Dewald Steyn

  • Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.

    Richard T Davey;Eduardo Fernández-Cruz;Norman Markowitz;Sarah Pett

  • Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

    Pedro Cahn;Jan Fourie;Beatriz Grinsztejn;Sally Hodder

  • Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.

    Chutitorn Ketloy;Anneke Engering;Utaiwan Srichairatanakul;Amporn Limsalakpetch

  • Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.

    Weerawat Manosuthi;Sasisopin Kiertiburanakul;Somnuek Sungkanuparph;Kiat Ruxrungtham

  • Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial

    Ananworanich J;Nuesch R;Le Braz M;Chetchotisakd P

Frequent Co-Authors

Jintanat Ananworanich
Jintanat Ananworanich Moderna Therapeutics (United States)
David A. Cooper
David A. Cooper University of New South Wales
Sharon R. Lewin
Sharon R. Lewin University of Melbourne
David M. Burger
David M. Burger Radboud University
Joep M. A. Lange
Joep M. A. Lange University of Amsterdam
Gail V. Matthews
Gail V. Matthews University of New South Wales
Sean Emery
Sean Emery University of New South Wales
Gregory J. Dore
Gregory J. Dore University of New South Wales
Matthew Law
Matthew Law University of New South Wales
Stephen Locarnini
Stephen Locarnini Melbourne Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare and research careers. For those interested in expanding their clinical skills, exploring accelerated NP programs can be an excellent way to advance quickly into nurse practitioner roles, combining immunology knowledge with hands-on patient care.

If you’re starting without a nursing background, consider online options like online ADN programs for non nurses. These programs provide foundational nursing education, paving the way toward careers that intersect with immunology in clinical settings.

For those aiming to become registered nurses efficiently, the easiest ABSN programs to get into offer practical pathways. These accelerated bachelor degrees balance rigorous coursework with flexibility, helping students step into immunology-adjacent roles faster.

Lastly, entry-level healthcare roles in immunology-related fields can start with programs like the easiest LPN programs to get into. Licensed Practical Nurse programs provide essential clinical training that supports roles in immunology labs or patient care settings.

Best Scientists Citing Kiat Ruxrungtham

Trending Scientists